Conclusion
When considering surgery, the benefits must be balanced against the risks and compared with the natural course. In this case, the benefits of vitreous surgery -that is, the release of vitreous traction that presumably arrests full thickness macular hole development, promotes hole closure, or improves visual function, must be weighed against the surgical risks and the clinical course without the surgery. The surgical efficacy is still questioned,18-2I because only limited natural history data are available for eyes with macular holes. 5 22-28 To investigate the natural outcome ofidiopathic macular holes, we reviewed the records of patients with stage 1, 2, 3, or 4 macular holes that were diagnosed after establishment of the Gass classification.
Subjects and methods
We studied retrospectively 154 patients (154 eyes) with idiopathic macular holes classified according to the Gass classification': stage 1 (macular cyst), 40 eyes; stage 2 (full thickness macular hole ',400 ,um with PVA around the hole29), 25 eyes; stage 3 (full thickness macular hole >400 ,urm with PVA around the hole), 58 eyes; and stage 4 (full thickness macular hole >400,um with PVS from the hole), 31 eyes. All patients had been examined within 3 months from symptom onset and followed for more than 1 year at the Schepens Retina Associates, Boston, from 1989 to 1994. The patients ranged in age from 48 to 84 (median 64) years. In patients with bilateral disease, only the initially affected eye was studied.
Detailed medical histories were obtained. Complete ocular examinations, including corrected Snellen visual acuity (VA), slitlamp biomicroscopy, indirect ophthalmoscopy, stereoscopic fumdus photography and 
No statistically significant difference was observed in these variables among the four groups.
STAGE 1 MACULAR HOLES
Of 40 eyes with a stage 1 lesion, 13 (33%) eyes had PVS from the macula, and 27 (68%) had PVA around the macula at the initial examination. Of the 13 eyes with PVS initially, the lesions resolved in 10 (77%) eyes and remained in three (23%) at the final examination. PVS from the macula developed in 11 eyes during the follow up period. Of these 11 eyes, the lesions resolved in nine (82%), remained stable in one (9%), and progressed to a full thickness hole in one (9%), the last of which developed a full thickness hole before PVS occurred. Of 16 eyes with persistent PVA, the lesions progressed to full thickness macular holes in eight (50%), and remained unchanged in eight (50%). Thus, of 40 eyes with a stage 1 lesion initially, nine (23%) eyes had a full thickness macular hole at the final examination. The percentage of eyes that developed a full thickness macular hole was significantly lower in eyes with PVS initially (0%, 0/13) than in eyes with PVA initially (33%, 9/27) (p<0'05). The follow up duration was not different between the two groups (median, 3 
years).
The median initial VA was 20/30 (range 20/20 to 20/70). During the follow up period, 12 (30%) eyes had an improved VA of two or more Snellen lines, 16 (40%) remained the same, and 12 (30%) had a decreased VA of two or more lines (Fig 1) . All nine eyes that developed a full thickness macular hole had decreased VA of two or more lines. The percentage of eyes with decreased VA was significantly lower in eyes with PVS initially (0/o, 0/13) than in eyes with PVA (44%, 12/27) (p<0 03).
STAGE 2 MACULAR HOLES
Of 25 eyes with a stage 2 lesion, 21 (84%) eyes had an enlarged macular hole; the remaining four (16%) eyes had a hole that remained stable during the follow up period. Four (57%) of seven eyes in which PVS from the macula developed during the follow up and 17 (94%) of 18 eyes in which PVA persisted during the follow up had an enlarged hole; in two eyes that developed PVS, the macular hole enlarged even after PVS occurred.
The median initial VA was 20/60 (range 20/30 to 20/200). During the follow up period, VAs decreased two or more lines in 17 (68%), and no eyes had improved VAs (Fig 1) : three (43%) of seven eyes in which PVS from the macula developed and 14 (78%) of 18 eyes in which PVA persisted had decreased VAs. STAGE 
MACULAR HOLES
The macular holes enlarged in 32 (55%) of 58 eyes, and remained stable in 26 (45%). During the follow up period, PVS from the macula developed in 16 (28%) of 58 eyes. The percentage of eyes with an enlarged macular hole was significantly lower in eyes that developed PVS (25%, 4/16) than in eyes that did not (67%, 28/42) (p<0'02).
The median initial VA was 20/200 (range 20/30 to 20/400). The VAs improved two or more lines in two (3%) eyes, were stable in 39 (67%), and decreased in 17 (29%) (Fig 1) .
STAGE 4 MACULAR HOLES
Of 31 eyes with stage 4 lesions, the macular holes enlarged in five (16%) eyes, remained stable in 25 (81%), and resolved in one (3%).
The median initial VA was 20/200 (range 20/30 to 20/400). VAs improved two or more lines in three (10%) eyes, remained stable in 24 (77%), and decreased in four (13%) (Fig 1) .
COMPARISON AMONG STAGES
The percentage of enlarged macular holes during the follow up period was significantly higher in stage 2 (84%) than in stages 3 (55%) or 4 (16%), and also higher in stage Establishing the diagnosis of macular hole is sometimes difficult and requires detailed fundus observation. However, this study had adequate inclusion criteria, which should have minimised the potential error. In the present study, the percentages of eyes with decreased VA, development of a full thickness hole from a cyst, or an enlarged hole agreed with those of previous studies.5 17 22-28 In this series, we determined the natural outcomes of the four stages of idiopathic macular holes. Because their outcomes vary, the management of idiopathic macular holes must be based on their stage at presentation. Our findings are important not only in terms of the management but also the future research of idiopathic macular holes, especially when a prospective clinical trial is conducted to investigate the value of vitreous surgery and the natural outcome of macular holes.
